Table 4.
Association of clinical characteristics and platinum sensitivity
| Characteristic | Platinum-sensitivity | Platinum-resistance | p* |
|---|---|---|---|
| Frequency (%) | Frequency (%) | ||
| Family History of Breast or Ovarian Cancer | |||
| No | 10 (55.6) | 8 (44.4) | 1.000 |
| Yes | 3 (60.0) | 2 (40.0) | |
| Histology | |||
| HGCS | 10 (52.6) | 9 (47.4) | 1.000 |
| Other histologies | 2 (66.7) | 1 (33.3) | |
| FIGO stage | |||
| I-III | 11 (55.0) | 9 (45.0) | 1.000 |
| IV | 2 (50.0) | 2 (50.0) | |
| Residual disease after primary surgery | |||
| < 1 cm | 12 (66.7) | 6 (33.3) | 0.014 |
| ≥ 1 cm | 0 (0) | 5 (100) | |
| Disease progression outside CNS | |||
| No | 8 (57.1) | 6 (42.9) | 1.000 |
| Yes | 6 (54.5) | 5 (45.5) | |
| Number of metastasis | |||
| 1 | 6 (66.7) | 3 (33.3) | 0.423 |
| > 1 | 7 (46.7) | 8 (53.3) | |
| Largest size of brain metastasis | |||
| < 3.2 cm (median) | 5 (50.0) | 5 (50.0) | 0.650 |
| ≥ 3.2 cm (median) | 6 (66.7) | 3 (33.3) | |
| Number of previous lines of CT | |||
| < 3 | 11 (78.6) | 3 (21.4) | 0.017 |
| s≥ 3 | 3 (27.3) | 8 (72.7) | |
| Death directly related to BM | |||
| No | 2 (40.0) | 3 (60.0) | 1.000 |
| Yes | 7 (53.8) | 6 (46.2) | |
HGSC High grade serous carcinoma, CNS Central nervous system, BM Brain metastasis *p values calculated with Exact Fisher’s test